高流量鼻导管与持续气道正压作为极早产儿初始呼吸支持的多中心随机对照试验方案(SIMPLSAFE3)
本研究为多中心随机阶梯楔形整群试验,拟纳入446例28+0至31+6周极早产儿,出生后即刻分别接受HFNC(8 L/min)或CPAP(6 cmH2O)初始呼吸支持,主要结局为无需正压通气即实现稳定。
要点
- 极早产儿出生后初始呼吸支持可选HFNC(8 L/min)或CPAP(6 cmH2O)。
- 主要结局为无需正压通气即达到稳定。
- 次要结局包括5分钟SpO2≥80%和10分钟SpO2>90%且FiO2≤0.40。
核心结论
- HFNC可能作为极早产儿出生时初始呼吸支持的安全有效替代方案,但需试验验证。
研究设计与样本
- 多中心、随机、阶梯楔形整群试验,计划纳入446例28+0至31+6周极早产儿,预计研究时长2年。
主要发现
- 原文未报告试验结果。
关键数值与推荐
- HFNC组流量8 L/min,CPAP组压力6 cmH2O,FiO2起始0.30。
- 出现心动过缓或持续低SpO2时启动正压通气。
- 主要结局为无需正压通气即实现稳定。
- 次要结局A:5分钟SpO2≥80%(允许≤2次短暂正压通气)。
- 次要结局B:10分钟SpO2>90%且FiO2≤0.40。
临床怎么用
- 试验结果可能为极早产儿出生时呼吸支持指南提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-invasive continuous positive airway pressure (CPAP) is the standard initial respiratory support for preterm infants. However, requirements such as optimal pressure delivery and facemask repositioning, which trigger unwanted reflexes and bradycardia, often necessitate the use of positive pressure ventilation (PPV). Findings from a pilot study suggested that high-flow nasal cannula (HFNC) may be a promising alternative to CPAP, with lower PPV requirements. We hypothesize that HFNC is a safe, effective, and user-friendly alternative to CPAP for stabilizing very preterm infants (28 + 0-31 + 6 weeks of gestation), potentially reducing the need for PPV. We aim to compare HFNC and CPAP as initial respiratory support strategies at birth. METHODS: This is a multicenter, randomized, stepped-wedge cluster trial. Infants will receive either HFNC (8 L/min) or CPAP (6 cmH2O) immediately after birth with tactile stimulation. The fraction of inspired oxygen (FiO2) will start at 0.30. PPV will be initiated if bradycardia or persistently low oxygen saturation (SpO2) occurs. The primary outcome is stabilization with the assigned support without PPV administration. Secondary outcomes include (A) achievement of SpO2 ≥ 80% at 5 min (with ≤ 2 brief PPV episodes) as a surrogate of safety and (B) achievement of SpO2 > 90% with FiO2 ≤ 0.40 at 10 min as a surrogate of efficacy. Overall, 446 infants will be recruited in both arms, with an estimated study duration of 2 years. DISCUSSION: The findings may inform future respiratory support guidelines for very preterm infants at birth. TRIAL REGISTRATION: ClinicalTrials.gov NCT06543589. Registered on August 9, 2024.
引用
- Lamberska T, Jonas K, Borcinova M, et al. High-flow nasal cannula versus continuous positive airway pressure for initial respiratory support in very preterm infants: study protocol for a multicenter randomized controlled trial (SIMPLSAFE3). Trials. 2026. PMID: 42286746. doi:10.1186/s13063-026-09816-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。